Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Glivec in Newly Diagnosed CML-CP (TOPS Korean Extension)
NCT01216085Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2010
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in chronic myeloid leukemia (CML), sponsored by Novartis. Started Aug 2010; status: completed.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01216085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01216085.